Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
- PMID: 15800947
- PMCID: PMC1951508
- DOI: 10.1002/ijc.21014
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
Abstract
Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in development as therapeutic agents. Methodologies to actively immunize against PSMA may be limited by immunologic ignorance and/or tolerance that restrict the response to self-antigens. Our studies have previously shown that xenogeneic immunization with DNA vaccines encoding melanosomal differentiation antigens induces immunity in a mouse melanoma model. Here we apply this approach to PSMA to establish proof of principle in a mouse model. Immunization with xenogeneic human PSMA protein or DNA induced antibodies to both human and mouse PSMA in mice. Monoclonal antibodies specific for mouse PSMA were generated to analyze antibody isotypes and specificity for native and denatured PSMA at the clonal level. Most antibodies recognized denatured PSMA, but C57BL/6 mice immunized with xenogeneic PSMA DNA followed by a final boost with xenogeneic PSMA protein yielded autoantibodies that reacted with native folded mouse PSMA. Monoclonal antibodies were used to confirm the expression of PSMA protein in normal mouse kidney. These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth.
Figures







Similar articles
-
DNA vaccines: an active immunization strategy for prostate cancer.Semin Oncol. 2003 Oct;30(5):659-66. doi: 10.1016/s0093-7754(03)00356-7. Semin Oncol. 2003. PMID: 14571413 Review.
-
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.Prostate. 2004 Sep 15;61(1):1-11. doi: 10.1002/pros.20074. Prostate. 2004. PMID: 15287089
-
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.Prostate. 2006 Sep 15;66(13):1359-70. doi: 10.1002/pros.20367. Prostate. 2006. PMID: 16894535
-
Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.Anticancer Res. 2005 Nov-Dec;25(6C):4727-32. Anticancer Res. 2005. PMID: 16334167
-
Monoclonal antibodies and prostate-specific membrane antigen.Curr Opin Investig Drugs. 2004 Jun;5(6):611-5. Curr Opin Investig Drugs. 2004. PMID: 15242249 Review.
Cited by
-
Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.World J Gastroenterol. 2007 May 7;13(17):2484-9. doi: 10.3748/wjg.v13.i17.2484. World J Gastroenterol. 2007. PMID: 17552033 Free PMC article.
-
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25. Cancer Res. 2009. PMID: 19706750 Free PMC article.
-
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829756 Free PMC article.
-
DNA vaccination for prostate cancer: key concepts and considerations.Cancer Nanotechnol. 2015;6(1):2. doi: 10.1186/s12645-015-0010-5. Epub 2015 Jul 2. Cancer Nanotechnol. 2015. PMID: 26161151 Free PMC article.
-
Improved cellular specificity of plasmonic nanobubbles versus nanoparticles in heterogeneous cell systems.PLoS One. 2012;7(4):e34537. doi: 10.1371/journal.pone.0034537. Epub 2012 Apr 3. PLoS One. 2012. Retraction in: PLoS One. 2017 Nov 2;12(11):e0187820. doi: 10.1371/journal.pone.0187820. PMID: 22509318 Free PMC article. Retracted.
References
-
- Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445–51. - PubMed
-
- Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35. - PubMed
-
- Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–30. - PubMed
-
- Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous